The Danish Cardiovascular Screening Trial (DANCAVAS)

ISRCTN ISRCTN12157806
DOI https://doi.org/10.1186/ISRCTN12157806
ClinicalTrials.gov number NCT03946410
Secondary identifying numbers N/A
Submission date
11/03/2015
Registration date
21/03/2015
Last edited
14/05/2024
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The significant increase in the average lifespan has resulted in an increase in medical and community resources needed to manage serious age-related diseases, such as cancer and cardiovascular disease (for example, heart disease and stroke). Routine medical checks by general practitioners are often not sufficient to identify a person developing cardiovascular disease. In this study, we aim to
investigate whether advanced cardiovascular screenings will prevent cardiovascular events (such as a heart attack) , and whether the possible health benefits are cost effective.

Who can participate?
Danish men aged between 65-74 years living in the Island of Fyn, and the communities of Vejle and Silkeborg in Denmark

What does the study involve?
Participants are randomly allocated into one of two groups. Those in group 1 are invited to attend an advanced cardiovascular screening examination. The screening includes detecting coronary artery disease and aneurysms (via the use of CT scans), blood pressure tests, tests to check heart rhythm and tests to check for high cholesterol levels and diabetes. Biological samples will be performed for biomarker and translational research. Participants in group 2 (control) receive their usual medical care and are not offered an advanced cardiovascular screening examination.

What are the possible benefits and risks of participating?
For participants in group 1 found to be developing cardiovascular disease, preventive actions, including medical treatment and possibly surgery, will be taken.

Where is the study run from?
Four hospital sites in the Island of Fyn, Vejle and Silkeborg (Denmark)

When is the study starting and how long is it expected to run for?
January 2014 to January 2026

Who is funding the study?
Region of Southern Denmark Research Group

Who is the main contact?
Professor Jes Lindholt

Contact information

Dr Jes Lindholt
Public

Department of Cardiothoracic and Vascular Surgery T
Odense
5000
Denmark

Study information

Study designRandomized, clinical controlled, interventional multicentre trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeScreening
Scientific titleThe Danish Cardiovascular Screening Trial (DANCAVAS): a large population-based randomized clinical multicenter trial testing combo cardiovascular screening in men aged 65-74 years
Study acronymDANCAVAS
Study hypothesisThe primary hypothesis is that the offer of an extensive circulatory screening and intervention programme fulfills the WHO criteria for screening especially concerning the significance of the diseases, the treatment benefits, and the cost effectiveness.
Ethics approval(s)Southern Denmark Region Committee on Biomedical Research Ethics (S-20140028) and the Data Protection Agency
ConditionCardiovascular disease
InterventionHalf of the study participants are randomised to the usual care without any screening (control group), while the other half of participants are invited to a screening and intervention programme that measures traditional risk factors, CAC, aneurysms, and PAD (screening group) and offer general cardiovascular prevention in case of positive finding.
Intervention typeMixed
Primary outcome measureAll cause mortality
Secondary outcome measures1. Costs and cost effectiveness after 3, 5 and 10 years to assess possible health and/or societal benefits of the screening.
2. Nationwide registry based information on health care consumption including contacts to GP and use of drugs, as well as hospital submissions.
Overall study start date01/01/2014
Overall study end date01/01/2026

Eligibility

Participant type(s)All
Age groupSenior
Lower age limit65 Years
Upper age limit74 Years
SexMale
Target number of participants45000
Total final enrolment47322
Participant inclusion criteriaDanish men aged 65-74 years old living in the Island of Fyn, and the communities of Vejle and Silkeborg in Denmark.
Participant exclusion criteria1. Women
2. Men younger than 65 years
Recruitment start date01/10/2014
Recruitment end date01/05/2017

Locations

Countries of recruitment

  • Denmark

Study participating centres

Odense University Hospital
Sdr. Boulevard 29
5000 Odense C
5000
Denmark
Vejle Sygehus
Kabbeltoft 25
Vejle
7100
Denmark
Regionshospitalet Silkeborg
Falkevej 3
Silkeborg
8600
Denmark

Sponsor information

The Region of Southern Denmark
Government

Damhaven 12
Vejle
7100
Denmark

ROR logo "ROR" https://ror.org/0290a6k23

Funders

Funder type

Not defined

Region of Southern Denmark Research Group (Region Syddanmarks Forskningspulje (Denmark))

No information available

Results and Publications

Intention to publish date01/07/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe entire study population, the controls as well as the screening group, will be monitored for a period of 10 years. The primary efficiency variable is overall mortality, while hospitalisations and deaths from cardiovascular diseases (cerebrovascular, cardiac, aneurysm, or other vascular) are the secondary variables. These endpoints are compared for the two groups using a Cox proportional hazards-regression analysis. The cost-efficiency calculation will be adjusted for the quality of life.
An independent endpoint committee will review registry data on the causes of death and data from the Danish National Patient Register concerning hospital admissions; supplemental data will be requested from hospitals and the GP if needed. The health economics of the screening program will be evaluated with two types of analyses. A trial-based evaluation will be conducted after 5 and 10 years of follow-up, whereas the lifetime perspective on the health economics of the screening will be evaluated in a separate decision analytic model for the men and women. First major publication date is planned for 1st of July 2018
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 05/12/2015 Yes No
Results article results 01/04/2020 06/11/2019 Yes No
Results article results 23/01/2020 12/03/2020 Yes No
Results article baseline results 27/03/2019 12/08/2021 Yes No
Results article results 10/08/2021 12/08/2021 Yes No
Statistical Analysis Plan version 6.0 03/01/2022 04/01/2022 No No
Results article 5-year follow-up 27/08/2022 30/08/2022 Yes No
Results article 5 year outcomes 13/10/2022 17/01/2023 Yes No
Statistical Analysis Plan version 7 17/01/2023 17/01/2023 No No
Other publications Post hoc analyses 13/05/2024 14/05/2024 Yes No

Additional files

ISRCTN12157806_SAP _v6.0_03Jan2022.pdf
30442 SAP 17Jan2023.pdf

Editorial Notes

14/05/2024: Publication reference added.
17/01/2023: The following changes were made to the trial record:
1. The statistical analysis plan (v7) was uploaded as an additional file.
2. Publication reference added.
30/08/2022: Publication reference added.
04/01/2022: The statistical analysis plan (SAP) has been uploaded.
12/08/2021: The following changes have been made:
1. Publication references added.
2. The total final enrolment number has been added from the reference.
3. The ClinicalTrials.gov number has been added from the reference.
12/03/2020: Publication reference added.
06/11/2019: Publication reference added.
08/12/2015: Publication reference added.